CN103880975B - 一种岩藻聚糖硫酸酯及其制备方法和在制备抗流感病毒药物中的应用 - Google Patents
一种岩藻聚糖硫酸酯及其制备方法和在制备抗流感病毒药物中的应用 Download PDFInfo
- Publication number
- CN103880975B CN103880975B CN201410132608.XA CN201410132608A CN103880975B CN 103880975 B CN103880975 B CN 103880975B CN 201410132608 A CN201410132608 A CN 201410132608A CN 103880975 B CN103880975 B CN 103880975B
- Authority
- CN
- China
- Prior art keywords
- fucoidan
- influenza
- virus medicament
- preparation
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000855 Fucoidan Polymers 0.000 title claims abstract description 99
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 241000700605 Viruses Species 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 206010022000 influenza Diseases 0.000 title claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 34
- 208000037797 influenza A Diseases 0.000 claims abstract description 19
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 17
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 17
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims abstract description 13
- 238000003809 water extraction Methods 0.000 claims abstract description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000001110 calcium chloride Substances 0.000 claims abstract description 10
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 238000001556 precipitation Methods 0.000 claims abstract description 8
- 150000004676 glycans Chemical class 0.000 claims abstract description 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 13
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
- 241000983746 Saccharina latissima Species 0.000 claims description 4
- 241001017629 Saccharina sculpera Species 0.000 claims description 4
- 239000003957 anion exchange resin Substances 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- 229940097043 glucuronic acid Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000000452 restraining effect Effects 0.000 abstract description 2
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000013641 positive control Substances 0.000 description 8
- 241000712431 Influenza A virus Species 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229960001028 zanamivir Drugs 0.000 description 5
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 5
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 3
- 229960003752 oseltamivir Drugs 0.000 description 3
- -1 polysaccharide compound Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410132608.XA CN103880975B (zh) | 2014-04-03 | 2014-04-03 | 一种岩藻聚糖硫酸酯及其制备方法和在制备抗流感病毒药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410132608.XA CN103880975B (zh) | 2014-04-03 | 2014-04-03 | 一种岩藻聚糖硫酸酯及其制备方法和在制备抗流感病毒药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103880975A CN103880975A (zh) | 2014-06-25 |
CN103880975B true CN103880975B (zh) | 2015-10-21 |
Family
ID=50950134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410132608.XA Active CN103880975B (zh) | 2014-04-03 | 2014-04-03 | 一种岩藻聚糖硫酸酯及其制备方法和在制备抗流感病毒药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103880975B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105748537B (zh) * | 2014-12-16 | 2021-04-09 | 吴彰哲 | 裙带菜乙醇萃取物在制备治疗或预防a型流感病毒感染的组合物中用途 |
CN105399848B (zh) * | 2015-11-20 | 2017-11-17 | 中国科学院上海药物研究所 | 一种岩藻聚糖硫酸酯、其制备方法和用途 |
CN106727668A (zh) * | 2016-12-17 | 2017-05-31 | 浙江工业大学 | 一种岩藻多糖在制备pc‑12细胞或mkn‑45细胞活性抑制剂中的应用 |
CN107522795A (zh) * | 2017-11-01 | 2017-12-29 | 泉州师范学院 | 一种提高海藻硫酸多糖提取率的方法 |
CN107828750B (zh) * | 2017-11-22 | 2020-11-10 | 青岛海大蓝科生物科技有限公司 | 一种海带gdp岩藻糖合成酶、及其编码基因和用途 |
CN114732823B (zh) * | 2019-03-13 | 2023-05-23 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
CN111748045B (zh) * | 2019-03-27 | 2022-01-07 | 天津医科大学 | 亨氏马尾藻岩藻聚糖硫酸酯制备方法及应用 |
JP7140940B2 (ja) * | 2020-08-05 | 2022-09-22 | 有限会社ハマショク | インフルエンザウイルスに対する抗ウイルス剤の製造方法 |
CN111973749B (zh) * | 2020-09-07 | 2023-03-21 | 威海人生药业集团股份有限公司 | 一种抗肿瘤免疫治疗的药物组合物 |
CN112220799A (zh) * | 2020-11-02 | 2021-01-15 | 江苏泰德医药有限公司 | 一种抑制病毒的产品及用途 |
CN112458126B (zh) * | 2020-11-26 | 2022-09-23 | 中国海洋大学 | 一种具有抗炎活性的半乳糖硫酸酯化合物的制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1209749A (zh) * | 1996-01-26 | 1999-03-03 | 宝酒造株式会社 | 细胞凋亡诱导物 |
CN1520458A (zh) * | 2001-04-18 | 2004-08-11 | �����﹤����ʽ���� | 硫酸化岩藻葡糖醛酸甘露聚糖 |
CN102488697A (zh) * | 2011-12-09 | 2012-06-13 | 中国海洋大学 | 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用 |
CN103539863A (zh) * | 2012-07-12 | 2014-01-29 | 中国科学院海洋研究所 | 褐藻来源的富含葡萄糖醛酸的低硫酸化杂聚糖在制备治疗帕金森病药物和保健品中的应用 |
-
2014
- 2014-04-03 CN CN201410132608.XA patent/CN103880975B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1209749A (zh) * | 1996-01-26 | 1999-03-03 | 宝酒造株式会社 | 细胞凋亡诱导物 |
CN1520458A (zh) * | 2001-04-18 | 2004-08-11 | �����﹤����ʽ���� | 硫酸化岩藻葡糖醛酸甘露聚糖 |
CN102488697A (zh) * | 2011-12-09 | 2012-06-13 | 中国海洋大学 | 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用 |
CN103539863A (zh) * | 2012-07-12 | 2014-01-29 | 中国科学院海洋研究所 | 褐藻来源的富含葡萄糖醛酸的低硫酸化杂聚糖在制备治疗帕金森病药物和保健品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103880975A (zh) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103880975B (zh) | 一种岩藻聚糖硫酸酯及其制备方法和在制备抗流感病毒药物中的应用 | |
Chen et al. | Structural characterization and antitumor activity of a polysaccharide from ramulus mori | |
Qiu et al. | Porphyran and oligo-porphyran originating from red algae Porphyra: Preparation, biological activities, and potential applications | |
Álvarez-Viñas et al. | Antiviral activity of carrageenans and processing implications | |
Geetha Bai et al. | Potential antiviral properties of industrially important marine algal polysaccharides and their significance in fighting a future viral pandemic | |
Mandal et al. | Xylans from Scinaia hatei: Structural features, sulfation and anti-HSV activity | |
Sun et al. | Studies on antiviral and immuno-regulation activity of low molecular weight fucoidan from Laminaria japonica | |
KR101063825B1 (ko) | 낙엽진흙버섯으로부터 추출한 항바이러스 활성을 갖는 약학조성물 | |
CN103539863B (zh) | 褐藻来源的富含葡萄糖醛酸的低硫酸化杂聚糖在制备治疗帕金森病药物和保健品中的应用 | |
Yingsakmongkon et al. | In vitro inhibition of human influenza A virus infection by fruit-juice concentrate of japanese plum (Prunus mume S IEB. et Z UCC) | |
Zheng et al. | Structural elucidation of a polysaccharide from Chrysanthemum morifolium flowers with anti-angiogenic activity | |
CN111234044B (zh) | 一种低分子量金耳葡糖醛酸-木甘聚糖及其制备方法和应用 | |
Ray et al. | Exploiting the amazing diversity of natural source-derived polysaccharides: modern procedures of isolation, engineering, and optimization of antiviral activities | |
CN104892793B (zh) | 桑黄菌丝体多糖、制备方法及其在抗肿瘤的应用 | |
CN112220799A (zh) | 一种抑制病毒的产品及用途 | |
CN104644711A (zh) | 一种艾纳香属植物提取物及其制备方法与应用 | |
CN102488697B (zh) | 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用 | |
CN108727509B (zh) | 一种毛竹笋壳阿拉伯半乳聚糖及其制备和用途 | |
CN105399848A (zh) | 一种岩藻聚糖硫酸酯、其制备方法和用途 | |
CN105924544A (zh) | 一种高硫酸化硫酸软骨素及其制备方法与应用 | |
CN105343121B (zh) | 聚古罗糖醛酸硫酸酯在制备抗乙型肝炎病毒的药物中的应用 | |
Yang et al. | Separation, characterization and hypoglycemic activity in vitro evaluation of a low molecular weight heteropolysaccharide from the fruiting body of Phellinus pini | |
Zhao et al. | Structural characterization of an alkali‐soluble polysaccharide from Angelica sinensis and its antitumor activity in vivo | |
Zhang et al. | Research progress on extraction, isolation, structural analysis and biological activity of polysaccharides from panax genus | |
CN103554290A (zh) | 一种肿节风酸性多糖及其制备方法、应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170323 Address after: 264200 Shandong Province, Zhang village, Weihai City Yong Jiang Street, No. 20 Patentee after: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Address before: 266100 Shandong Province, Qingdao city Laoshan District Songling Road No. 238 Patentee before: Ocean University of China |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Fucoidan and its preparation method and application in the preparation of anti influenza drugs Effective date of registration: 20220526 Granted publication date: 20151021 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006536 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230602 Granted publication date: 20151021 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006536 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A fucoidan Organosulfate and its preparation method and application in the preparation of anti influenza virus drugs Effective date of registration: 20230606 Granted publication date: 20151021 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980042918 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20151021 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980042918 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A fucoidan sulfate ester and its preparation method, as well as its application in the preparation of anti influenza virus drugs Granted publication date: 20151021 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980022070 |